• David B Shultz, Leslie A Modlin, Priya Jayachandran, Rie Von Eyben, Iris C Gibbs, Clara Y H Choi, Steven D Chang, Griffith R Harsh, Gordon Li, John R Adler, Steven L Hancock, and Scott G Soltys.
• Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
• Int. J. Radiat. Oncol. Biol. Phys. 2015 Aug 1;92(5):993-9.

PurposeTo report the outcomes of repeat stereotactic radiosurgery (SRS), deferring whole-brain radiation therapy (WBRT), for distant intracranial recurrences and identify factors associated with prolonged overall survival (OS).Patients And MethodsWe retrospectively identified 652 metastases in 95 patients treated with 2 or more courses of SRS for brain metastases, deferring WBRT. Cox regression analyzed factors predictive for OS.ResultsPatients had a median of 2 metastases (range, 1-14) treated per course, with a median of 2 courses (range, 2-14) of SRS per patient. With a median follow-up after first SRS of 15 months (range, 3-98 months), the median OS from the time of the first and second course of SRS was 18 (95% confidence interval [CI] 15-24) and 11 months (95% CI 6-17), respectively. On multivariate analysis, histology, graded prognostic assessment score, aggregate tumor volume (but not number of metastases), and performance status correlated with OS. The 1-year cumulative incidence, with death as a competing risk, of local failure was 5% (95% CI 4-8%). Eighteen (24%) of 75 deaths were from neurologic causes. Nineteen patients (20%) eventually received WBRT. Adverse radiation events developed in 2% of SRS sites.ConclusionMultiple courses of SRS, deferring WBRT, for distant brain metastases after initial SRS, seem to be a safe and effective approach. The graded prognostic assessment score, updated at each course, and aggregate tumor volume may help select patients in whom the deferral of WBRT might be most beneficial.Copyright © 2015 Elsevier Inc. All rights reserved.

27 keywords...

hide…